Clinical Trial Update: Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intranasal ketamine for pain control during vaso-occlusive episodes in children with sickle cell disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Vaso-occlusive Crisis

Drugs mentioned

• Ketamine (intranasal) (ketamine)

Snippet

Sponsor: Abigail Nixon | Conditions: Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Status: TERMINATED